How donor and recipient genes affect fat in a transplanted liver in MASH cirrhosis
Studies how PNPLA3 and MBOAT7 gene variations relate to fatty grafts after liver transplant.
Plain-language title generated from the registry record
Registry title: Influence of Donor and Recipient Genetic Polymorphisms on Graft Steatosis After Liver Transplant
Key facts
- Where
- New Delhi, IndiaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who had a living donor liver transplant for MASH-related chronic liver disease at ILBS at least 3 years before the study, and their donors.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Chronic liver disease or cirrhosis related to MASH
- Earlier treatment
- A living donor liver transplant at ILBS at least 3 years before the start of this study
Main reasons for not taking part
- Children under 18 years
- Transplant done for acute liver failure or acute-on-chronic liver failure
Read by machine on 13 November 2026.
Where in India
- Institute of Liver and Biliary SciencesNew Delhi, IndiaContact: Naren Mandalapu, MSTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Institute of Liver and Biliary Sciences, India
- Trial code
- NCT07685353
- Record updated
- 21 July 2026
- Original description
MASH (Metabolic Dysfunction-associated Steatohepatitis) is among the most common indications for liver transplantation.The metabolic syndrome persists after liver transplant and is often further exacerbated among MAFLD patients, thereby leading to recurrence of MAFLD in the allograft. MAFLD is a complex phenotype, dynamic interactions between both genetic and environmental factors are likely to shape disease susceptibility and progression.Read full original descriptionShow less
Influence of Donor and Recipient PNPLA3 and MBOAT7 Gene Polymorphisms on Graft Liver Steatosis After Living Donor Liver Transplant for Metabolic Dysfunction-associated Steatohepatitis (MASH) Related Cirrhosis
MASH (Metabolic Dysfunction-associated Steatohepatitis) is among the most common indications for liver transplantation.The metabolic syndrome persists after liver transplant and is often further exacerbated among MAFLD patients, thereby leading to recurrence of MAFLD in the allograft. MAFLD is a complex phenotype, dynamic interactions between both genetic and environmental factors are likely to shape disease susceptibility and progression.
Genetic and epidemiological studies, indicates strong heritability of hepatic fat content.Family studies demonstrate that first degree relatives of patients with MAFLD are at a much higher risk of the disease than the general population.Most of the data available is regarding Deceased Donor Liver Transplant and Western population.Most studies have studied single gene variant but fatty liver is a polygenic trait.No study was done exclusively in MASH recipients.
In this study we aim to study the effect of recipient and donor PNPLA3, MBOAT7 gene variations, and other clinical \& laboratory data on graft liver steatosis in liver transplant recipients. We also propose to compare the outcomes of genetically related donors vs unrelated donors, to know the influence of genetic factors vis-a-vis environmental factors.
Inclusion: All LDLT recipients with MASH related CLD and their donors who underwent their surgery at ILBS at least 3 years prior to the onset of this study.
Exclusion: Pediatric (<18 years); Transplants for ALF/ ACLF.